Danicamtiv, a selective agonist of cardiac myosin, for dilated cardiomyopathy: A Phase 2 open-label trial

Journal:

Journal of the American College of Cardiology

Published:

2025-10-01

DOI:

10.1016/j.jacc.2025.09.1511

Affiliations:

22

Authors:

27

Go to article

Institutions	Authors	Share
Kardigan, United States of America (USA)	9.000000	0.33
Brigham and Women's Hospital (BWH), United States of America (USA)	3.000000	0.11
Bristol-Myers Squibb, United States of America (USA)	2.000000	0.07
Mayo Clinic, United States of America (USA)	1.000000	0.04
Institute of Health Carlos III (ISCIII), Spain	1.000000	0.04
UCL, United Kingdom (UK)	1.000000	0.04
The Ohio State University (OSU), United States of America (USA)	1.000000	0.04
Heidelberg University (Uni Heidelberg), Germany	1.000000	0.04
University Hospital of Würzburg (UKW), JMU, Germany	1.000000	0.04
Hospital Universitario Virgen de la Arrixaca, Spain	1.000000	0.04
University of California, San Diego (UC San Diego), United States of America (USA)	1.000000	0.04
Prolaio, United States of America (USA)	1.000000	0.04
Austin Heart, United States of America (USA)	1.000000	0.04
Institute of Biomedical Research of A Coruña (INIBIC), Spain	0.500000	0.02
Massachusetts General Hospital Cancer Center, United States of America (USA)	0.500000	0.02
Baim Institute for Clinical Research, United States of America (USA)	0.500000	0.02
Hospital Universitario Puerta de Hierro Majadahonda, UAM, Spain	0.500000	0.02
Royal Brompton Hospital, United Kingdom (UK)	0.333333	0.01
Harefield Hospital, United Kingdom (UK)	0.333333	0.01
Imperial College London (ICL), United Kingdom (UK)	0.333333	0.01

Interested in Cardiovascular Medicine and Haematology?